Physician profile
Marcus Messmer
NPI 1285070490
$25,966.27
in general payments reported to CMS, 2019-2025
26 companies · $19K in 2025
The $19K reported for 2025 was more than what 87% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.08 · 2022: $84.79 · 2023: $581 · 2024: $6,376 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $2,387 · Travel and Lodging: $950 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,696.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,725.00 |
| Food and Beverage | $2,386.65 |
| Travel and Lodging | $950.08 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $15,367.55 | 2024-2025 | Monjuvi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $5,775.77 | 2024-2025 | Calquence, Enhertu |
| F. Hoffmann-La Roche Ag | $2,911.67 | 2024 | Polivy |
| Beigene USA, INC. | $394.11 | 2022-2024 | Brukinsa |
| Genentech USA, INC. | $328.93 | 2023-2025 | Polivy, Lunsumio, Columvi |
| Adc Therapeutics America, INC. | $298.61 | 2023-2025 | |
| Daiichi Sankyo INC. | $191.54 | 2021-2025 | Vanflyta, Enhertu |
| Beone Medicines USA, INC. | $148.88 | 2025 | Brukinsa |
| Janssen Biotech, INC. | $124.68 | 2024 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $74.96 | 2024-2025 | |
| Celgene Corporation | $58.54 | 2024-2025 | Reblozyl |
| Morphosys, US INC. | $40.51 | 2023 | Monjuvi |
| Pharmacosmos Therapeutics INC. | $38.55 | 2025 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $29.77 | 2023 | Imbruvica |
| Regeneron Pharmaceuticals, INC. | $28.97 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $26.67 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $26.33 | 2024 | Somatuline Depot, Onivyde |
| Alexion Pharmaceuticals, INC. | $23.53 | 2024 | Ultomiris |
| Eisai INC. | $21.15 | 2024 | |
| Merck Sharp & Dohme LLC | $19.31 | 2024 | Lynparza, Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $19.15 | 2025 | |
| Glaxosmithkline, LLC. | $17.09 | 2024 | Ojjaara |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Messmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.